USD 0.0
(0.0%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | 1439.59 | 1409.74 | 1631.01 | 1678.96 | 1964.14 | 9394.49 |
Gross Profit | -1439.59 | -1409.74 | -1631.01 | -1678.96 | -1964.14 | -9394.49 |
Operating Expenses | 1.41 Million | 1.6 Million | 1.78 Million | 1.84 Million | 2.66 Million | 3.03 Million |
Selling, General and Administrative Expenses | 1.41 Million | 1.6 Million | 1.78 Million | 1.84 Million | 2.66 Million | 3.03 Million |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | - | - | - | - | - | - |
Cost and Expenses | 1.41 Million | 1.6 Million | 1.78 Million | 1.84 Million | 2.66 Million | 3.04 Million |
Operating Income | -1.41 Million | -1.6 Million | -1.78 Million | -1.84 Million | -2.66 Million | -3.04 Million |
Interest Expense | 107.95 Thousand | 41.17 Thousand | 55.33 Thousand | 68.72 Thousand | 70.37 Thousand | 29.3 Thousand |
Income Tax Expense | 2.41 | -1687.12 | -2653.25 | -2657.77 | -2168.50 | 0.51 |
Earnings before Tax | -1.53 Million | -1.65 Million | -1.83 Million | -1.92 Million | -2.78 Million | -3.09 Million |
Net Income | -1.53 Million | -1.65 Million | -1.83 Million | -1.92 Million | -2.78 Million | -3.09 Million |
Earnings Per Share Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
Earnings Per Share Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
Weighted Average Shares Outstanding | 230.42 Million | 230.42 Million | 193.45 Million | 171.85 Million | 161.7 Million | 161.7 Million |
Weighted Average Shares Outstanding (Diluted) | 230.42 Million | 230.42 Million | 193.45 Million | 171.85 Million | 161.7 Million | 161.7 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | -1.42 Million | -2 Million | -2.07 Million | -2.19 Million | -3.13 Million | -3.48 Million |
Earnings Before Tax Margin | - | - | - | - | - | - |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | 352.93 | 352.86 | 1439.59 | 360.65 | 349.65 | 360.60 |
Gross Profit | -352.93 | -352.86 | -1439.59 | -360.65 | -349.65 | -360.60 |
Operating Expenses | 309.19 Thousand | 331.17 Thousand | 1.41 Million | 340.49 Thousand | 330.61 Thousand | 355.43 Thousand |
Selling, General and Administrative Expenses | 309.19 Thousand | 331.17 Thousand | - | 340.49 Thousand | 330.61 Thousand | 355.43 Thousand |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | 221.37 Thousand | - | - | - | - | - |
Cost and Expenses | 309.54 Thousand | 331.53 Thousand | 1.41 Million | 340.85 Thousand | 330.96 Thousand | 355.79 Thousand |
Operating Income | -309.54 Thousand | -331.53 Thousand | -1.41 Million | -340.86 Thousand | -330.96 Thousand | -355.79 Thousand |
Interest Expense | 54.41 Thousand | 50.29 Thousand | 107.95 Thousand | 45.43 Thousand | 30.17 Thousand | 23.49 Thousand |
Income Tax Expense | -1.93 | 2.14 | 2.41 | 1.35 | -830.32 | -857.75 |
Earnings before Tax | -351.28 Thousand | -370.34 Thousand | -1.53 Million | -373.63 Thousand | -365.37 Thousand | -378.69 Thousand |
Net Income | -351.28 Thousand | -370.34 Thousand | -1.53 Million | -373.63 Thousand | -365.37 Thousand | -378.69 Thousand |
Earnings Per Share Basic | -0.00 | -0.00 | - | -0.00 | -0.00 | -0.00 |
Earnings Per Share Diluted | -0.00 | -0.00 | - | -0.00 | -0.00 | -0.00 |
Weighted Average Shares Outstanding | 230.42 Million | 230.42 Million | 230.42 Million | 230.42 Million | 230.42 Million | 230.42 Million |
Weighted Average Shares Outstanding (Diluted) | 230.42 Million | 230.42 Million | 230.42 Million | 230.42 Million | 230.42 Million | 230.42 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | -309.19 Thousand | -331.17 Thousand | - | -340.49 Thousand | -330.61 Thousand | -355.42 Thousand |
Earnings Before Tax Margin | - | - | - | - | - | - |
8112
AUXIF
0021
DMYD-B
CNQQF
SPELS